Ignite Creation Date:
2025-12-24 @ 12:02 PM
Ignite Modification Date:
2026-01-29 @ 12:50 PM
Study NCT ID:
NCT02588261
Status:
TERMINATED
Last Update Posted:
2024-12-10
First Post:
2015-10-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Sponsor:
Astellas Pharma Global Development, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
8273-CL-0302
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None